Line 6: | Line 6: | ||
<div class="column full_size"> | <div class="column full_size"> | ||
<h1>Description</h1> | <h1>Description</h1> | ||
+ | |||
+ | |||
<p>Each pic links to own page that describe the disease and diagnostic problems in full</p> | <p>Each pic links to own page that describe the disease and diagnostic problems in full</p> | ||
<br> | <br> | ||
Line 16: | Line 18: | ||
<p> center: Pic of diagnostic - link to design page</p> | <p> center: Pic of diagnostic - link to design page</p> | ||
<p> Brief solution to problem </p> | <p> Brief solution to problem </p> | ||
+ | <p>By 2016, HIV still affected 36.7 million people across the globe. 71% of those people live in sub-Saharan Africa; over half of them do not know they are HIV positive. Although the developed world considers HIV a manageable disease, many sub-Saharan African countries have morality rates as high as 761 deaths per 100,000. Furthermore, not knowing one’s HIV status causes several problems: spreading the disease further and decreasing life expectancy as well as quality of life from not receiving treatment. In many of these countries, ARVs are free and readily available through numerous nonprofit organizations. It was found that 86% of people who know they are HIV+ proceed to take ARVs; better diagnostics is needed in order to help decrease the burden of disease caused by HIV. Our goal as a team is to fill this need by creating a test that would allow many of these people who do not know their status to find out. </p> | ||
+ | |||
+ | <p>However, diagnosing HIV is problematic in this region. In Rwanda specifically, an HIV positive test costs on average over $1300 USD. This may not be a lot for those who have health insurance in first world countries; however, the average hourly wage in Rwanda is $0.53/hr USD. In order to pay for a single HIV positive test, a person who works 40 hours a week would need to work for over 1 year consecutively with no other expenses. This is completely unreasonable. The economic factors associated with getting diagnosed are massive and need to be reduced. One way to do this is to create a reliable rapid test that is as affordable as possible. | ||
+ | </p> | ||
+ | |||
+ | |||
+ | <p>Another barrier to diagnosis in the region is access to these tests. Current laboratory tests are not only expensive but they are also located in laboratories. The laboratories can be days away on foot from people. Oftentimes, these people cannot afford to go to the clinic because they need time off work and transportation itself is costly, and/or too hard. These machines also require equipment and electricity; things that are uncommon in rural parts of sub-Saharan Africa. Overall, the issue of diagnosis in this region is massive but consists of several key issues. | ||
+ | </p> | ||
+ | |||
+ | |||
+ | <p> Another factor that contributes to the overall cost of the tests is the recovery of the protein. To make the downstream recovery easier, a thermo-stable variant of the lectin can be engineered to ensure that it will not denature if the lysate of cells is heated. This makes the overall process much more simple, which means that the production of GRFT becomes more cost effective. | ||
+ | </p> | ||
+ | |||
+ | |||
+ | <p>As for Zika, it is a disease that is mostly spread via mosquito but it causes microcephaly and Guillain-Barre Syndrome in infants when in uteri of infected mothers. Both of these neurological diseases are severe and mothers are in a unique situation when pregnant in regions or when recently returned from a trip to a Zika infected country. Zika is a unique case as many of the antibodies individuals produce in response to the infection are cross reactive with tests we have for Dengue and Chikungunya, two very prevalent diseases in the same region as Zika. This is an issue because if a person has ever been infected with either of these diseases, current rapid tests for Zika would be positive, even if the individual has never had Zika. The tests that indisputably determine whether or not a person has Zika are expensive and require very specialized equipment. In the US, there are currently only three labs that are approved to run this test. | ||
+ | </p> | ||
+ | |||
+ | <p>The lateral flow assay that we designed is modular so it will not only help one of these diseases but both of them.</p> | ||
<hr> | <hr> |
Revision as of 00:16, 30 October 2017
Description
Each pic links to own page that describe the disease and diagnostic problems in full
left align: handdrawn pic of HIV -- right side brief HIV diagnostic problems
25% offset from top pic of Zika -- right side brief Zika diagnostic problem
left side brief GRFT overview -- right side handdrawn GRFT pic
center: Pic of diagnostic - link to design page
Brief solution to problem
By 2016, HIV still affected 36.7 million people across the globe. 71% of those people live in sub-Saharan Africa; over half of them do not know they are HIV positive. Although the developed world considers HIV a manageable disease, many sub-Saharan African countries have morality rates as high as 761 deaths per 100,000. Furthermore, not knowing one’s HIV status causes several problems: spreading the disease further and decreasing life expectancy as well as quality of life from not receiving treatment. In many of these countries, ARVs are free and readily available through numerous nonprofit organizations. It was found that 86% of people who know they are HIV+ proceed to take ARVs; better diagnostics is needed in order to help decrease the burden of disease caused by HIV. Our goal as a team is to fill this need by creating a test that would allow many of these people who do not know their status to find out.
However, diagnosing HIV is problematic in this region. In Rwanda specifically, an HIV positive test costs on average over $1300 USD. This may not be a lot for those who have health insurance in first world countries; however, the average hourly wage in Rwanda is $0.53/hr USD. In order to pay for a single HIV positive test, a person who works 40 hours a week would need to work for over 1 year consecutively with no other expenses. This is completely unreasonable. The economic factors associated with getting diagnosed are massive and need to be reduced. One way to do this is to create a reliable rapid test that is as affordable as possible.
Another barrier to diagnosis in the region is access to these tests. Current laboratory tests are not only expensive but they are also located in laboratories. The laboratories can be days away on foot from people. Oftentimes, these people cannot afford to go to the clinic because they need time off work and transportation itself is costly, and/or too hard. These machines also require equipment and electricity; things that are uncommon in rural parts of sub-Saharan Africa. Overall, the issue of diagnosis in this region is massive but consists of several key issues.
Another factor that contributes to the overall cost of the tests is the recovery of the protein. To make the downstream recovery easier, a thermo-stable variant of the lectin can be engineered to ensure that it will not denature if the lysate of cells is heated. This makes the overall process much more simple, which means that the production of GRFT becomes more cost effective.
As for Zika, it is a disease that is mostly spread via mosquito but it causes microcephaly and Guillain-Barre Syndrome in infants when in uteri of infected mothers. Both of these neurological diseases are severe and mothers are in a unique situation when pregnant in regions or when recently returned from a trip to a Zika infected country. Zika is a unique case as many of the antibodies individuals produce in response to the infection are cross reactive with tests we have for Dengue and Chikungunya, two very prevalent diseases in the same region as Zika. This is an issue because if a person has ever been infected with either of these diseases, current rapid tests for Zika would be positive, even if the individual has never had Zika. The tests that indisputably determine whether or not a person has Zika are expensive and require very specialized equipment. In the US, there are currently only three labs that are approved to run this test.
The lateral flow assay that we designed is modular so it will not only help one of these diseases but both of them.
Tell us about your project, describe what moves you and why this is something important for your team.
What should this page contain?
- A clear and concise description of your project.
- A detailed explanation of why your team chose to work on this particular project.
- References and sources to document your research.
- Use illustrations and other visual resources to explain your project.
Advice on writing your Project Description
We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be consist, accurate and unambiguous in your achievements.
Judges like to read your wiki and know exactly what you have achieved. This is how you should think about these sections; from the point of view of the judge evaluating you at the end of the year.
References
iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.
Inspiration
See how other teams have described and presented their projects: